Compilation Services for
Pharmaceutical Companies Canada

A compilation engagement under CSRS 4200 (effective December 2021, replacing the old Notice to Reader standard) is a CPA service where the accountant assembles the pharmaceutical company's annual financial statements from management-provided information — without performing audit or review verification procedures. Here is what makes pharmaceutical compilations uniquely complex: Drug development cost accounting policy: the engagement letter must specify whether drug development costs will be expensed as incurred (the conservative and most common approach for private pharma) or whether the company will attempt to capitalize development costs under ASPE Section 3064 (requires meeting all six criteria: technical feasibility, intention to complete, ability to use or sell, probable future benefit, adequate resources, ability to measure cost reliably). In practice, most private CCPC pharmaceutical companies expense all development costs — because: (a) the criteria for capitalization are rarely met until very late in development; (b) expensing development costs maximizes the annual SR&ED refundable credit; (c) early-stage pharma companies rarely have life sciences investors requiring IFRS-style capitalization. Three-tier drug inventory: unlike simple retail or service businesses, pharmaceutical manufacturers maintain inventory across three distinct accounting stages: raw materials (API and excipients at landed cost including import duty); WIP (in-process drug batches at accumulated batch cost from the manufacturing record); finished goods (QC-released drug products at total manufacturing cost, with mandatory NRV write-downs for near-expiry or expired products). The CPA must obtain a complete drug inventory listing with batch numbers, lot numbers, and expiry dates before the compilation can be finalized. SR&ED reconciliation: the compiled income statement's R&D expense lines must be consistent with the SR&ED T661 claim. SR&ED eligible expenditures (scientist salaries, qualifying materials, eligible CRO fees) must be in a separate income statement account from non-SR&ED R&D costs (Phase III clinical, regulatory submission, QC). CRA SR&ED auditors routinely request financial statements to verify SR&ED claim consistency. Revenue recognition complexity: pharmaceutical revenue includes drug product sales (with chargebacks, returns, and rebate provisions), licensing fees (upfront right-to-use vs. ongoing right-to-access treatments), milestone payments (recognize only when achieved, not when anticipated), and royalties (accrual basis based on licensee sales in each period). Each revenue type has a different recognition policy that must be disclosed in the compiled statement notes. What the CPA does NOT do in a compilation: does not verify laboratory records; does not confirm that milestone criteria have been met; does not assess the probability of drug development success; does not verify import duty calculations on API purchases; does not confirm royalty statements are accurate. These are management's responsibilities — acknowledged in the engagement letter. The Compilation Report explicitly states these limitations, and sophisticated pharmaceutical investors understand what a compilation does and does not provide.

SR&ED is the most important tax incentive for Canadian pharmaceutical companies — and its correct integration with the compiled financial statements is critical for both the tax credit and for investor confidence. Here is the complete guide: Credit rates for pharmaceutical CCPCs (2026): CCPC with associated group taxable income under $500,000 and associated group capital under $15,000,000 (full refundable rate): 35% refundable credit on the first $3,000,000 of eligible SR&ED expenditures. CCPC above the income or capital threshold (phase-out): the refundable portion phases out; above $800,000 associated group taxable income: the enhanced refundable rate begins to phase out. Non-CCPC or CCPC above thresholds: 15% non-refundable credit. Foreign-controlled pharmaceutical companies: 15% non-refundable (cannot be CCPCs). Qualifying activities in pharmaceutical development: Drug discovery and lead optimization: systematic screening of compound libraries against therapeutic targets; SAR (structure-activity relationship) studies to optimize potency and selectivity; computational chemistry approaches to molecular design. Preclinical pharmacology: in vitro and in vivo studies investigating mechanism of action, PK/PD relationships, and toxicology — when the outcome of each study was genuinely uncertain and required systematic experimental design. Formulation development: developing novel drug formulations (sustained-release, targeted delivery, nanoparticulate formulations, improved bioavailability) where the technological challenge is genuine and the solution required systematic experimental work beyond routine formulation optimization. Analytical method development: developing novel analytical methods for drug characterization, impurity profiling, or stability testing where existing compendial methods are demonstrably inadequate for the specific application. Manufacturing process development: developing new synthetic routes, purification processes, or sterile manufacturing processes where the technical challenge required systematic experimental investigation. Non-qualifying pharmaceutical activities: Routine quality control testing against established specifications; clinical trials: Phase III and Phase IV human clinical trials are generally not eligible; however, Phase I and Phase II may have qualifying activities if genuine technological uncertainty exists about safety or mechanism (distinct from the clinical trial per se); regulatory submission preparation (Health Canada NOC, NDS, ANDS filing); pharmacovigilance and post-market surveillance; business development, licensing negotiations; market research; manufacturing scale-up using established techniques; technology transfer (transferring a known process from one facility to another). SR&ED claim structure for pharmaceutical companies: Eligible expenditure categories: salary and wages: all wages and employer CPP/EI for employees who perform qualifying SR&ED activities, at the % of their time attributable to qualifying work. A scientist spending 70% of their time on qualifying research: 70% of their total compensation is eligible. Overhead: the proxy method (65% of eligible salaries) is most commonly used — it eliminates the need to track every overhead dollar and provides a conservative but defensible overhead amount. The traditional method (tracking actual overhead by project) may produce a higher eligible overhead amount but requires more detailed documentation. Materials consumed: laboratory reagents, APIs used in formulation development studies, animal study materials, test compounds — materials that were consumed in the SR&ED process (destroyed or materially changed). Not eligible: capital equipment (the equipment is capitalized and depreciated — it is not consumed). Contractor costs: 80% of fees paid to arm's-length contractors for SR&ED services are eligible — CRO fees for preclinical studies, if the study involves genuine technological uncertainty, at 80% of the invoice; foreign CRO fees may also qualify at 80%. Documentation requirements for pharmaceutical SR&ED: CRA strongly emphasizes contemporaneous documentation — records created at or near the time of the work. For pharmaceutical SR&ED: laboratory notebooks with dated entries showing experimental design, observations, and conclusions; batch records for formulation development experiments; analytical data with systematic interpretation; project plans showing technological objectives; team meeting notes discussing technical problems and results; principal investigator sign-off on study reports. CRA SR&ED auditors have pharmaceutical-specific technical officers who review the scientific merit of pharmaceutical SR&ED claims — the documentation must be scientifically rigorous as well as administratively complete. The financial statement integration: the compiled income statement must have separate accounts for SR&ED-eligible and non-SR&ED R&D costs; the SR&ED eligible amounts on the income statement must match the amounts claimed on the T661; the SR&ED refundable credit is NOT revenue — it is a reduction of income tax expense on the income statement and an income tax receivable on the balance sheet (until received from CRA, typically 6–12 months after the fiscal year-end). If SR&ED cash is advanced through an SR&ED bridge loan (Espresso Capital, BDC, or third-party SR&ED lenders): the advance is a current liability (not revenue) until CRA issues the refund; the loan is repaid from the CRA SR&ED refund when received.

Drug development cost accounting is the most consequential financial reporting decision for Canadian pharmaceutical companies — affecting the income statement, the balance sheet, the SR&ED claim, and investor perception simultaneously. Here is the complete framework: The two approaches under Canadian private company ASPE: Approach 1 — Expense all R&D as incurred (dominant approach for private pharma): under ASPE Section 3064.25, research costs must be expensed as incurred — there is no option to capitalize research costs. For development costs (activities after the research phase): a company MAY expense development costs if the company cannot demonstrate all six capitalization criteria are met. In practice, most Canadian private pharmaceutical companies choose to expense all development costs because: (1) The ASPE Section 3064 criteria for capitalizing development costs are extremely difficult to meet in drug development, given the high failure rate; (2) Expensing creates larger R&D deductions that immediately reduce taxable income; (3) Expensing creates larger SR&ED eligible expenditures that increase the annual refundable credit; (4) Conservative financial statement presentation is preferred by most life sciences investors who are sophisticated enough to add-back development expenses in their valuation models. Approach 2 — Capitalize development costs when ASPE 3064 criteria are met: the six criteria (all must be met simultaneously): (1) Technical feasibility of completing the intangible asset (the drug) so it will be available for use or sale — requires demonstrating the drug can be developed to a commercially viable form. (2) The enterprise intends to complete the asset — management must have a documented intention to see the drug through to commercialization. (3) The enterprise has the ability to use or sell the intangible asset — either internal use (for drugs used in-house) or a commercial market for the completed drug. (4) Probable future economic benefit — the drug will either generate revenue or reduce costs. This is the most challenging criterion in pharmaceutical development because of the high failure rate. (5) The enterprise has the technical, financial, and other resources to complete the development — management must demonstrate it has (or has reasonable access to) the resources needed to complete the program. (6) The enterprise can reliably measure the expenditure attributable to the intangible asset — the cost must be identifiable to the specific drug program. In pharmaceutical development: criteria (2), (3), (5), and (6) are typically demonstrable from the project plan and budget. Criteria (1) and (4) are the challenging ones. Technical feasibility (#1) is typically not established until Phase II clinical success or pre-NDS meeting acceptance. Probable future benefit (#4) is typically not established until Phase II or Phase III success, given that only ~10% of drug candidates entering Phase I ultimately receive regulatory approval. Practical guidance for stage-of-development: pre-clinical stage (discovery through IND): expense all; Phase I: expense all; Phase II (proof of concept): may be the point where capitalization becomes possible for specific well-defined programs with strong interim data — discuss with CPA at this stage; Phase III: capitalization may be appropriate for individual programs with Phase II success and active Health Canada engagement; post-approval development (new indications, line extensions): capitalization appropriate when the specific program meets all criteria. The SR&ED interaction and the expensing advantage: a pharmaceutical CCPC with $600,000 in annual development staff costs: if expensed: all $600,000 creates an income statement R&D deduction + SR&ED eligible expenditure → $210,000 refundable SR&ED credit (35% × $600,000); if capitalized: the $600,000 is a balance sheet asset; no income statement deduction in the year of incurrence; no SR&ED eligible expenditure in the year (SR&ED is based on incurred expenditures, not capital assets); amortization of the capitalized costs (when they begin) is not SR&ED-eligible. For most private CCPC pharmaceutical companies with limited cash flow: expensing all development costs and maximizing the SR&ED refundable credit provides $210,000+ in annual cash that would be foregone under capitalization. Changing the accounting policy: if a company has been capitalizing development costs and later decides to expense them (or vice versa): an accounting policy change requires disclosure in the compilation notes; comparative financial statements should be restated to reflect the new policy from the earliest period presented (retrospective application); discuss the change with the CPA before year-end to understand the full implications for the current year and prior year comparatives.

Drug product inventory valuation for pharmaceutical manufacturers requires understanding both standard manufacturing accounting (three-tier inventory) and pharmaceutical-specific factors (expiry dates, GMP batch records, quarantine status, regulatory compliance implications of inventory decisions). Here is the comprehensive framework: Raw Materials (API and excipients): pharmaceutical raw materials are valued at landed cost — the complete cost to bring the material into the facility: Supplier invoice price (in CAD; translate foreign currency invoices at the rate on the date of import); International freight (ocean or air freight from supplier to Canadian port); Canadian customs duty (confirmed from the B3 CBSA form — duty rate depends on the HS tariff classification of the API and country of origin); Customs broker fee (allocated across the shipment proportionally); Import GST (5% of the CBSA-assessed value) — NOTE: the import GST is recoverable as an ITC, so it is NOT included in inventory; record it as GST/HST Receivable. Pharmaceutical-specific raw material considerations: Each API batch must be tracked separately by batch number, expiry date, and QC release status. Quarantine inventory (received but not yet QC-released) is still an asset on the balance sheet but should be disclosed separately from QC-released material — it cannot be used in production until released. Expiry date management: APIs within 6 months of expiry that cannot be used before expiry must be written down to NRV (which may be zero for controlled substances). Work-in-Progress (WIP): drug formulations in process are valued at accumulated batch cost to date: Direct materials: APIs and excipients dispensed from inventory for the specific batch (at their cost per the raw material cost records). Direct labour: pharmacists, laboratory technicians, production operators for the time applied to the batch — at their wage rate including employer CPP and EI. Manufacturing overhead: GMP facility overhead allocated to the batch — typically based on direct labour hours or machine hours; includes: GMP facility rent (or mortgage interest); pharmaceutical equipment CCA (mixing tanks, tablet presses, encapsulation machines, coaters — Class 8 at 20%); calibration and maintenance of production equipment; environmental monitoring costs; production supervision. The batch manufacturing record (BMR) is the primary WIP documentation for pharmaceutical compilations: it records every material dispensed, every production step, every in-process test result, and every deviation. The BMR provides the accumulated batch cost for each WIP batch. Failed batch write-off: if an in-process batch fails a critical in-process test: the batch must be written off immediately to zero (or net salvage value of recoverable components); a formal deviation report in the batch record documents the failure; the write-off is charged to COGS (or as a separate quality cost line). Finished Goods: completed drug products (batches that have passed final QC release) are valued at total manufacturing cost (API + excipients + direct labour + GMP overhead). The lower of cost and NRV rule under ASPE: NRV for commercial drug products: typically the selling price less the costs to complete and sell. However, pharmaceutical NRV complications: short-dated drug products (within 6 months of expiry): pharmacies and distributors will not accept short-dated product; NRV may be significantly below manufacturing cost; NRV assessment required — if NRV is below cost: write down to NRV at year-end. Expired drug products: Health Canada regulations require destruction of expired product; NRV = zero. Products subject to mandatory recall: Health Canada may mandate a recall due to safety, contamination, or quality concerns; all recalled product must be written off immediately to zero — destruction is legally required. Products pending Health Canada compliance action: if Health Canada has issued a Notice of Concern or compliance order, affected product may have NRV concerns — discuss with management and legal counsel. Regulatory archive samples: Health Canada requires pharmaceutical manufacturers to retain archive samples of each commercial drug batch (reference standards, finished product samples) for the shelf life of the product plus one year. These samples are inventory (at manufacturing cost) but are never available for sale. Separate account recommended (1225 — Regulatory Archive Samples). Write-off schedule: as each sample set exceeds its required retention period, write off to QC/regulatory expense. GMP compliance implications of inventory valuation: Health Canada's Division 2 GMP regulations require pharmaceutical manufacturers to maintain accurate inventory records by batch number, lot number, and expiry date. The pharmaceutical company's inventory management system (or the manual batch records) is the primary source document for the compilation inventory schedule. A pharmaceutical company without complete batch records and expiry date tracking has both a GMP compliance problem and a compilation documentation problem — the CPA cannot finalize the inventory without this documentation.

Canadian pharmaceutical companies need compiled financial statements in more situations than most other industries — due to the combination of significant tax incentives (SR&ED), investor scrutiny (life sciences VCs), licensing partner requirements, and complex regulatory compliance. Here is the complete guide: 1. Annual T2 corporate tax return and SR&ED claim (most important): every incorporated Canadian pharmaceutical company must file a T2. For pharmaceutical companies: the T2 Schedule 125 (income statement) must correctly present R&D expenses with the SR&ED-eligible and non-SR&ED split that is consistent with the T661 SR&ED claim; the T2 Schedule 100 (balance sheet) must present drug inventory at three tiers with correct GIFI codes; the T661 SR&ED form must be consistent with the financial statement R&D expense lines — CRA SR&ED auditors request the financial statements as part of any SR&ED review. The annual SR&ED credit ($100,000–$500,000+ for active R&D companies) is the primary non-dilutive cash source for pre-revenue pharmaceutical companies — the compilation is the foundation that ensures the SR&ED claim is defensible. 2. Life sciences investment due diligence: Canadian life sciences investors require formal financial statements for any investment consideration: seed and angel ($250K–$2M): may accept compiled statements; early VC ($2M–$10M): typically requires compiled ASPE statements; Series A and beyond ($10M+): typically requires reviewed ASPE statements (more assurance than compilation). Life sciences investors specifically examine in the compiled statements: drug development cost accounting policy (do they expense or capitalize, and is the policy appropriate?); SR&ED credit history (confirming non-dilutive cash flow from CRA); milestone and licensing revenue (confirming the business model is generating external validation); drug inventory write-down history (confirming inventory quality management). 3. Licensing and co-development negotiations: when a Canadian pharmaceutical company seeks a licensing partner, a co-development partner, or is being considered for acquisition, the partner's business development and finance teams require a formal data room including compiled financial statements. The licensing partner specifically reviews: R&D investment by drug program (confirming the level of investment in the asset being licensed); regulatory compliance costs (confirming Health Canada compliance is maintained); manufacturing COGS (confirming commercial viability of the drug's manufacturing cost). A compiled set of ASPE statements by a Canadian CPA with pharmaceutical experience provides credibility that self-prepared records do not. 4. Government grants and funding programs: CIHR (Canadian Institutes of Health Research) Industry Partnership grants; NSERC Strategic Partnership Grants; NRC-IRAP grants above $500,000; Genome Canada grants; provincial life sciences programs (BCIF, MaRS Investment Accelerator Fund, BioAlberta); all require financial statements for applications above certain thresholds. Government grant reviewers confirm: the applicant has the financial capacity to execute the proposed research; prior government funding was properly used and accounted for; the company is not in financial distress. 5. GMP equipment financing (BDC and chartered banks): pharmaceutical manufacturers investing in production equipment require bank or BDC financing. GMP pharmaceutical equipment represents significant capital investments: bioreactors ($50,000–$2,000,000+); tablet presses and encapsulation machines ($50,000–$500,000); HPLC analytical systems ($30,000–$200,000); lyophilizers ($100,000–$1,000,000+); aseptic fill-finish lines ($500,000–$5,000,000+). BDC and chartered banks require compiled financial statements for equipment loans. The CPA's compilation demonstrates: EBITDA (or net income plus SR&ED credit plus amortization) for debt service coverage; working capital adequacy; the overall financial health of the pharmaceutical business. 6. Health Canada licensing and compliance requirements: while Health Canada's GMP regulations don't formally require compiled financial statements, practical situations where they support regulatory processes include: Drug Establishment Licence (DEL) renewal if financial viability is questioned; Good Manufacturing Practice (GMP) audit support (demonstrating the company has financial resources to maintain compliance); drug shortage reporting to Health Canada (compiled statements may be requested to assess whether a shortage is financially driven).